A New Era in Therapy

Against Blindness

66% of blindness in Europe and the US is caused by retinal diseases - and thus preventable.

Our Mission

deepeye empowers the field of ophthalmology with AI-driven optimal therapy planning support, enabling additional insights into treatment data of patients suffering from retinal eye diseases. These conditions such as Age-related Macular Degeneration (AMD) are prevalent in over 12% of the European and US population, causing more than 66% of cases of blindness. Through our precision medicine platform, we aim to address the root causes of these vision impairments.

Our Partners

Logo unseres Partners Bayer
Logo unseres Partners Heidelberg Engineering
Logo unseres Partners Topcon Healthcare

What Sets Us Apart

The Digital Therapy Assistant

At deepeye, weโ€™re pioneering a shift in retinal therapy through our specialized AI tools for ophthalmology. Our innovation supports the therapy process, enabling doctors to make more informed decisions, thereby improving patient outcomes.

Highlights of AI 2nd opinion


Darstellung von ร„rzten bei der Auswertung von OCT-Bildern.

Ease of Adoption

Seamless Path to Advanced Ophthalmic Solutions

At deepeye, we've engineered our solution to ensure a seamless transition for doctors. Our integration with popular imaging software and collaboration with major OCT device manufacturers significantly lowers the barrier to entry, making the adoption of our innovative AI tools straightforward.


Highlights

Revolutionizing Clinical Studies with deepeyeยฎ Research

Discover the future of clinical studies with deepeyeยฎ Research, a cutting-edge AI platform transforming retinal therapy research. Our approach, honed through Europe's leading clinical methodologies, propels deepeyeยฎ to the forefront of innovation in anti-VEGF trials.


Highlights

deepeyeยฎ Research is more than just a tool. It is a partnership in advancing precision medicine, enhancing clinical research, and shaping the future of need-based retinal therapy.

graphische Auswertung einer von deepeye medical durchgefรผhrten Studie